SE204642C1 - - Google Patents
Info
- Publication number
- SE204642C1 SE204642C1 SE204642DA SE204642C1 SE 204642 C1 SE204642 C1 SE 204642C1 SE 204642D A SE204642D A SE 204642DA SE 204642 C1 SE204642 C1 SE 204642C1
- Authority
- SE
- Sweden
- Prior art keywords
- phenyl
- carbon atoms
- group
- triazolidine
- oxo
- Prior art date
Links
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
KLASS INTERNATIONELLSVENSK C07 d12 p:10/0 PATENT- OCH REGISTRERINGSVERKET Ans. 5411/1964 inkom den 30/4 1964 utlagd den 27/9 196 FARBWERKE HOECHST AG VORMALS MEISTER LUCIUS & BRVNING, FRANKFURT A.M., FORBUNDSREPUBLIKEN TYSKLAND Satt for framstillning av triazolidiner Upplinnare: H Ruschig, K Schmitt, L Ther och VT Pfaff Prior itet begard fretn den 4 mars 1960 (Forbundsrepubliken Tyskland) Foreliggande uppfinning avser ett forfarande for framstallning av nya triazolidiner med for-mein I:I: NH—C=0 I \A (I), 111R, 0 i vilken R, betecknar en Irate- eller halogenatom, en alkyl- eller alkoxigrupp med 1-4 kolatomer och R, en hydroxigrupp, en halogenatom, en alkoxigrupp med 1-4 kolatomer, en halogenalkoxi- eller hydroxi-alkoxigrupp med upp till 4 kolatomer, en fenoxi- eller bensyloxigrupp, i vilken en vateatom i godtycklig stallning av fenylkarnan kan vara substituerad med en halogenatom eller med en alkyl- eller alkoxigrupp med upp till 4 kolatomer, eller en alifatisk acylaminogrupp med upp till 4 kolatomer, och deras salter, vilket kanneteeknas darav, att man i tiotriazolider av allmanna formeln II // \/--11\I A /\\/\ / R ersatter svavelatomen med en syreatom och eventuellt med hjalp av oorganiska eller organiska baser jived& de erhallna foreningarna till motsvarande salter. CLASS INTERNATIONAL SWEDISH C07 d12 p: 10/0 PATENT AND REGISTRATION AGENCY Ans. 5411/1964 was received on 30/4 1964 issued on 27/9 196 FARBWERKE HOECHST AG VORMALS MEISTER LUCIUS & BRVNING, FRANKFURT AM, FEDERAL REPUBLICEN GERMANY Set for the production of triazolidines Inventors: H Ruschig, V it Pgetard, L Therf, L Ther The present invention relates to a process for the preparation of new triazolidines of the form I: I: NH - C = O I \ A (I), 111R, 0 in which R or halogen atom, an alkyl or alkoxy group having 1-4 carbon atoms and R, a hydroxy group, a halogen atom, an alkoxy group having 1-4 carbon atoms, a haloalkoxy or hydroxyalkoxy group having up to 4 carbon atoms, a phenoxy or benzyloxy group, in which a hydrogen atom in any position of the phenyl nucleus may be substituted by a halogen atom or by an alkyl or alkoxy group having up to 4 carbon atoms, or an aliphatic acylamino group having up to 4 carbon atoms, and their salts, which may be characterized by solids of general formula II // \ / - 11 \ I A / \\ / \ / R replace the sulfur atom with an oxygen atom and possibly with the help of inorganic or organic bases jived & the obtained compounds to the corresponding salts.
De nya triazolidinerna utgora, samtidigt som de aro val fysiologiskt fOrdragbara, vardefulla lakemedel med i synnerhet antiflogistiska egenskaper. The new triazolidines, while being physiologically tolerable, are valuable drugs with particularly antiphlogistic properties.
Som substituenter R, och R, i den allmarma formeln I for fOrfarandeprodukterna ma exempelvis namnas foljande: 11.1: Va.te, fluor, klor, brom, jod, metyl, etyl, propyl, isopropyl, n-butyl, isobutyl, sek.butyl, tert.butyl, metoxi, etoxi, n-propoxi, isopropoxi, n-butoxi, sek.butoxi, isobutoxi; R2: fluor, klor, brom, jod, hydroxi, metoxi, etoxi, n-propmd, isopropoxi, n-butoxi, sek.butoxi, isobutoxi, fl-hydroxi-etoxi, bensyloxi, o-, m- eller p-metoxibensyloxi, fenoxi, o-, in- eller p-metoxifenoxi, p-klor-fenoid, o-metyl-fenoxi, formylamino, acetamino, butyrylamino, f3-k1or-etoxi. As substituents R 1 and R 2 in the general formula I for the process products, the following may be mentioned, for example: 11.1: Hydrogen, fluorine, chlorine, bromine, iodine, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl , tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy; R2: fluorine, chlorine, bromine, iodine, hydroxy, methoxy, ethoxy, n-propamide, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, fl-hydroxyethoxy, benzyloxy, o-, m- or p-methoxybenzyloxy, phenoxy, o-, in- or p-methoxyphenoxy, p-chloro-phenoid, o-methyl-phenoxy, formylamino, acetamino, butyrylamino, f3-chloro-ethoxy.
Substituenterna kunna befinna sig i godtycklig stallning av fenylkarnan. The substituents may be in any position of the phenyl nucleus.
Som utgangsmaterial for forfarandet enligt uppfinningen ma exempelvis namnas: 1-feny1-4-(p-etoxi-feny1)-3-oxo-5-tio-1,2,4-triazolidin, 1-feny1-4-(2,3- eller 4-metoxi-feny1)-3-oxo-5-tio1,2,4-triazolidin, 1-feny1-4-(2- eller 3-etoxi-feny1)-3-oxo-5-tio-1,2,4- triazolidin, 1-feny1-4-(4-hydroxi-feny1)-3-oxo-5-tio-1,2,4- triazolidin, C X R2 2 1-(4-metoxi-feny1)-4-(4-metcod-feny1)-3-oxo-5- tio-1,2,4-triazolidin, 1-(2,3- eller 4-metyl-feny1)-4-(2,3- eller 4-etcod- feny1)-3-oxo-5-tio-1,2,4-triazolidin, 1-feny1-4-(4-acetylamino-feny1)-3-oxo-5-tio-1,2,4- triazolidin, 1-feny1-4-(4-klor-feny1)-3-oxo-5-tio-1,2,4-triazoli- din, 1-feny1-4-(4-n-propoxi-feny1)-3-oxo-5-tio-1,2,4- triazolidin, 1-feny1-4-(4-bensylcod-feny1)-3-oxo-5-tio-1,2,4- triazolidin, 1-feny1-4-(4-fenoxi-feny1)-3-oxo-5-tio-1,2,4-triazo- 11din, 1-(4-klor-fenyI)-4-(4-etoxi-feny1)-3-oxo-5-tio- 1,2,4-triazolidin, 1-(2,3- eller 4-n-propyl-fenyI)-4-(4-isopropoxifeny1)-3-oxo-5-tio-1,2,4-triazolidin. Examples of starting materials for the process according to the invention are: 1-phenyl-4- (p-ethoxy-phenyl) -3-oxo-5-thio-1,2,4-triazolidine, 1-phenyl-4- (2,3 or 4-methoxy-phenyl) -3-oxo-5-thio1,2,4-triazolidine, 1-phenyl-4- (2- or 3-ethoxy-phenyl) -3-oxo-5-thio-1, 2,4-triazolidine, 1-phenyl- 4- (4-hydroxy-phenyl) -3-oxo-5-thio-1,2,4-triazolidine, CX R2 2 1- (4-methoxy-phenyl) -4 - (4-Methodec-phenyl) -3-oxo-5-thio-1,2,4-triazolidine, 1- (2,3- or 4-methyl-phenyl) -4- (2,3- or 4- (4-oxo-5-thio-1,2,4-triazolidine), 1-phenyl-4- (4-acetylamino-phenyl) -3-oxo-5-thio-1,2,4-triazolidine , 1-phenyl- 4- (4-chloro-phenyl) -3-oxo-5-thio-1,2,4-triazolidine, 1-phenyl- 4- (4-n-propoxy-phenyl) -3 -oxo-5-thio-1,2,4-triazolidine, 1-phenyl-4- (4-benzylcod-phenyl) -3-oxo-5-thio-1,2,4-triazolidine, 1-phenyl-4 - (4-phenoxy-phenyl) -3-oxo-5-thio-1,2,4-triazo-11-dine, 1- (4-chloro-phenyl) -4- (4-ethoxy-phenyl) -3-oxo -5-thio-1,2,4-triazolidine, 1- (2,3- or 4-n-propyl-phenyl) -4- (4-isopropoxyphenyl) -3-oxo-5-thio-1,2, 4-triazolidine.
Utbytet av svavelatomen i tiotriazolidinerna av formeln II mot syre är en vad betraffar tillampningen pa andra utgangsmaterial tidigare i princip kand reaktion. Man anvander harvid lampligen ett oxidationsmedel sasom kaliumpermanganat, vilket i kyla snabbt inverkar pa en t. ex. i vattenhaltigt alkali upplost tiotriazolidin. Reaktionen ledes lampligen till slut genom mattlig varmning och reaktionslosningen avsuges frail den bildade mangandioxiden. Vid surgorningen av filtratet erMies triazolidinen. Man kan dven ersatta svavlet med hjalp av en tungmetalloxid, t. ex. kvicksilveroxid, med syre och arbetar harvid lampligen i ett inert organiskt losningsmedel sasom bensen, toluen, knmen eller cymen under anvandande av temperaturer over 100° C, foretradesvis c:a 150° C, varvid omsattningen eventuellt maste utforas i autoklav. Forfarandeprodukternas rening sker genom omkristallisering eller utfallning med syror ur alkalisk losning. The exchange of the sulfur atom in the thiotriazolidines of the formula II for oxygen is a reaction known in principle to the application to other starting materials. An oxidizing agent such as potassium permanganate is suitably used, which in the cold quickly acts on a e.g. in aqueous alkali dissolved thiotriazolidine. The reaction is finally led by slow heating and the reaction solution is sucked off from the manganese dioxide formed. When acidifying the filtrate, Mies is the triazolidine. You can then replace the sulfur with the help of a heavy metal oxide, e.g. mercury oxide, with oxygen and working therein suitably in an inert organic solvent such as benzene, toluene, cinnamon or cymene using temperatures above 100 ° C, preferably about 150 ° C, the reaction having to be carried out in an autoclave. Purification of the process products takes place by recrystallization or precipitation with acids from alkaline solution.
De vid forfarandet enligt uppfinningen erhallna 3,5-dioxo-1,2,4-triazolidinerna utgora foreningar med sur karaktar, vilka p5. vanligt satt med hjalp av oorganiska och organiska baser kunna Overforas till motsvarande salter. Som oorganiska 'baser ma exempelvis namnas; alkali- eller jordalkalihydroxider, -alkoholater eller -hydrider, f0- retradesvis natriumhydroxid, -metylat, -etylat, -hydrid-, magnesiumhydrcodd och kalciumhydr'oxid. Som organiska baser lampa sig i synnerhet alifatiskt substituerade aminer, sasom 13-dimetylAminoetanol, /3-dietylaminoetanol, dietanolamin, trietanolamin, dietanolmetylamin m. fl. Med avseende pa anvandningen som lakemedel ha i synnerhet de motsvarande alkali- och jordalkalisalterna betydelse, vilka i de fiesta fall aro losliga i vatten och vilkas lOsningar ha ett fysiologiskt godtagbart pH-varde. The 3,5-dioxo-1,2,4-triazolidines obtained in the process according to the invention constitute compounds of acidic character, which p5. usually sat with the help of inorganic and organic bases can be Transferred to the corresponding salts. Examples of inorganic bases are; alkali or alkaline earth metal hydroxides, alcohols or hydrides, respectively sodium hydroxide, methylate, ethylate, hydride, magnesium hydrocode and calcium hydroxide. Particularly suitable organic bases are aliphatically substituted amines, such as 13-dimethylaminoethanol, β-diethylaminoethanol, diethanolamine, triethanolamine, diethanolomethylamine and others. With regard to their use as medicaments, the corresponding alkali and alkaline earth salts are particularly important, which in most cases are soluble in water and whose solutions have a physiologically acceptable pH value.
Forfarandeprodukterna utgbra vardefulla lakemedel. De ha i synnerhet antiflogistiska egenskaper, men uppvisa ocksa. t. ex. blodtryckssankande, analgetisk avensom (koronar)-karlvidgandeverkan och utmarka sig i allmanhet for sin goda fysiologiska fordragbarhet. Salunda visar t. ex 1-fenyl4 - (4- etcod - fenyl) - 3,5 - dioxo -1,2,4 - triazolidinnatriumsaltet vid aerosiltest ph en rattass vid en dosering av 500 mg/kg subkutant en kraftig, lange varande antiflogistisk verkan. LD„ utgor hos moss vid intravenos applicering c:a 800 mg/kg, varav framgar, att preparatet har en avsevard terapeutisk bredd. FOrfarandeprodukternas kraftiga antiflogistiska verkan Or overraskande, emedan det vid provning av kanda triazolidiner, t. ex. 1,4-difenyl-, 1-(p-metyl-feny1)-4-fenyl avensom 1- feny1-4- (p-metyl-feny1)-3,5-dioxo-1,2,4-triazolidin, konstaterats, att dessa foreningar icke ha nagon antiflogistisk verkan. The process products constitute valuable drugs. They have particularly anti-phlogistic properties, but also exhibit. e.g. antihypertensive, analgesic avensom (coronary) vasodilator effect and stand out in general for its good physiological tolerability. Salunda, for example, 1-phenyl4- (4-encod-phenyl)-3,5-dioxo-1,2,4-triazolidine sodium salt in aerosil test ph shows a steering wheel at a dose of 500 mg / kg subcutaneously a strong, long-lasting antiflogistic effect. LD 'in moss during intravenous application is about 800 mg / kg, from which it appears that the preparation has a considerable therapeutic breadth. The strong antiphlogistic effect of the process products is surprising, since when testing canda triazolidines, e.g. 1,4-diphenyl-, 1- (p-methyl-phenyl) -4-phenyl avensom 1-phenyl- 4- (p-methyl-phenyl) -3,5-dioxo-1,2,4-triazolidine, found , that these associations have no antiphlogistic effect.
Forfarandeprodukterna kunna appliceras som sadana eller i form av sina motsvarande salter, eventuellt under inblandning av farmaceutiskt brukliga fasta eller flytande bararmaterial, sasom vatten, vegetabiliska oljor, starkelsearter eller hjalpmaterial, exempelvis stabiliserings-, konserverings-, vat- eller emulgermedel, oralt eller parenteralt i form av tabletter, drageer, kapslar, ltisningar, suspensioner etc. Betraffande den orala administreringen ifragakomma som ingivningsformer fOretradesvis tabletter eller drageer, till vilka forfarandealstren i egenskap av aktiva substanser bearbetas med de vanliga bararmaterialen, sasom mjolksocker, starkelse, gummi, dragant och magnesiumstearat. Doseringen ph manniskor Jigger i allmanhet mellan 50 och 200 mg per administrationsenhet. The process products can be applied as such or in the form of their corresponding salts, optionally with admixture of pharmaceutically acceptable solid or liquid bar materials, such as water, vegetable oils, starches or excipients, for example stabilizers, preservatives, aqueous or emulsifying agents, orally or parenterally in in the form of tablets, dragees, capsules, capsules, suspensions, etc. Concerning the oral administration may be used as administration forms, preferably tablets or dragees, to which the process ingredients as active substances are processed with the usual bar materials, such as milk sugar, starch, gum, magnesium, tragacanth. The dosage ph people Jigger is generally between 50 and 200 mg per administration unit.
Exempel. 1-feny1-4-(p-etoxi-feny1)-3,5-dioxo-1, 2,4-triazolidin. Example. 1-phenyl- 4- (p-ethoxy-phenyl) -3,5-dioxo-1,2,4-triazolidine.
En alkalisk losning av 6 g 1-feny1-4-(p-etoxifeny1)-3-oxo-5-tio-1,2,4-triazolidin av smaltpunkten 240-243° C (framstalld genom kondensation av fenylhydrazin-p-karbonsyra-etylester-a-tiokarbonsyra-klorid med p-fenetidin och efterfeljande behandling med natronlut) behandlas med kaliumpermanganat i ringa overskott och reaktionen slutfOres genom svag varmning. Man avlagsnar en eventuellt kvarblivande gran fargning genom tillsats av nagra droppar metanol, avsuger fran mangandioxiden och surgor filtratet. Efter omkristallisering ur alkohol smalter 1-feny1-4-(petoxi-feny1)-3,5-dioxo-1,2,4-triazolidin vid 193195° C. An alkaline solution of 6 g of 1-phenyl- 4- (p-ethoxyphenyl) -3-oxo-5-thio-1,2,4-triazolidine, m.p. 240-243 ° C (prepared by condensation of phenylhydrazine-p-carboxylic acid -ethyl ester-α-thiocarboxylic acid chloride with p-phenetidine and subsequent treatment with sodium hydroxide solution) are treated with potassium permanganate in small excess and the reaction is completed by gentle heating. Any remaining spruce staining is removed by adding a few drops of methanol, aspirating from the manganese dioxide and acidifying the filtrate. After recrystallization from alcohol, 1-phenyl- 4- (petoxy-phenyl) -3,5-dioxo-1,2,4-triazolidine melts at 193195 ° C.
Natriumsaltet av 1-feny1-4-(p-etoxi-feny1)-3,5- dioxo-1,2,4-triazolidin kan t. ex. ur isopropanol genom tillsats av beraknad mangd natriummetylat erhallas i form av val utpraglade kristaller. The sodium salt of 1-phenyl- 4- (p-ethoxy-phenyl) -3,5-dioxo-1,2,4-triazolidine can e.g. from isopropanol by the addition of an estimated amount of sodium methylate is obtained in the form of selected pronounced crystals.
Analys: Ci61-124N202Na 1H20 Beraknad: C 57,0 H 4,8 N 12, Funnen:C 56,9 H 4,8 N 12,6 Beraknad: Na 6,8 11,0 5,3 Funnen: Na 6,8 H20 5,2 Analysis: C 161-124N 2 O 2 Na 1H 2 O Calculated: C 57.0 H 4.8 N 12, Found: C 56.9 H 4.8 N 12.6 Calculated: Na 6.8 11.0 5.3 Found: Na 6, 8 H 2 O 5.2
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE204642T |
Publications (1)
Publication Number | Publication Date |
---|---|
SE204642C1 true SE204642C1 (en) | 1965-01-01 |
Family
ID=41988089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE204642D SE204642C1 (en) |
Country Status (1)
Country | Link |
---|---|
SE (1) | SE204642C1 (en) |
-
0
- SE SE204642D patent/SE204642C1/sv unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2083683C (en) | Stable formulation of analapril salt, a process for the preparation thereof and the use thereof | |
NO810684L (en) | PROCEDURE FOR THE PREPARATION OF INDANDER DERIVATIVES. | |
CN102803214A (en) | New compounds, pharmaceutical composition and methods relating thereto | |
SE9901573D0 (en) | New compounds | |
JPH0784386B2 (en) | Composition for tablet preparation | |
KR890016009A (en) | 1,2,5,6-tetrahydropyridine derivatives, methods for their preparation, their use as medicaments and compositions containing them | |
EP0315401A3 (en) | Xanthine derivatives and their preparation and pharmaceutical formulation | |
US9415047B2 (en) | Use of benzo five-membered nitrogen heterocyclic piperazine or piperidine derivatives | |
IE36337L (en) | Pharmaceutical compositions | |
SE204642C1 (en) | ||
IL60217A (en) | 4'-deoxyparomomycin derivatives,process for their preparation and pharmaceutical compositions containing them | |
WO2000066550A8 (en) | New compounds | |
DK151806B (en) | METHOD OF ANALOGUE FOR THE PREPARATION OF VINCAMINE SUCCHARINATE | |
GB2075499A (en) | Nonaprenylamine derivatives | |
CA2373962A1 (en) | Immediate release medicinal compositions for oral use | |
DE69816456T2 (en) | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR THE MANUFACTURE OF A MEDICAMENT ACTING FOR TGF-BETA-1 | |
KR0177894B1 (en) | Antidepressant | |
AU592851B2 (en) | Transdermal formulations | |
PT69808A (en) | Process for preparing new n1-benzoyl-n2-phenyl-1,3-diaminopropan-2-ols and salts thereof | |
JPH05262747A (en) | Therapeutic agent for ulcerative colitis | |
CA1155459A (en) | Decaprenylamine derivatives | |
JPH0395116A (en) | Reverse transcriptase-inhibiting composition | |
KR890014116A (en) | Hypertension Therapy Mixture | |
JPH0733333B2 (en) | Brain function improving drug | |
BR0315713A (en) | Compound, compound preparation process, pharmaceutical composition, glucose lowering methods, disease prevention or treatment and compound use |